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Abstract: Ectonucleotide Pyrophosphatase Phosphodiesterase 1 (ENPP1) 
is a class II membrane glycoprotein with two unrelated properties: It can 
hydrolyze extracellular nucleotides and downregulate insulin receptor 
signaling. The present study was carried out to investigate whether 
common single-nucleotide polymorphism K121Q (rs1044498) of the 
ENPP1 gene is associated with Acute Coronary Syndrome (ACS) in the 
representatives of Ukrainian population and to assess if the risk depends on 
gender and Body Mass Index (BMI). A total 228 DNA samples (118 ACS 
patients and 110 control subjects) were genotyped for the polymorphism by 
PCR and restriction fragment length polymorphism method. No 
associations between the K121Q polymorphisms and ACS were found 
neither on the whole nor taking into account the gender. However, in the 
persons with BMI <25 kg/m
2
 but not with overweight, genotypes with the 
minor allele (KQ + QQ) were significantly associated with ACS (OR 3.939, 
95% CI 1.148-13.524, P = 0.029). Genotypes with minor allele can be a 
possible genetic risk factor for ACS in persons with BMI <25 kg/m
2
. It is 
likely that these genotypes affect ACS not by the traditional risk factors 
(overweight/obesity, insulin resistance and type 2 diabetes) but by direct or 
undirect influence on pathologic processes in the wall of the coronary 
vessels (atherosclerosis and arterial calcification). 
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Introduction 
Ectonucleotide Pyrophosphatase Phosphodiesterase 1 
(ENPP1), also known as plasma cell membrane 
glycoprotein 1 (PC-1), belongs to a class II membrane 
glycoprotein which is widely expressed in many organs and 
tissues of the human and animal organisms (liver, skeletal 
muscle, heart, brain, kidney, lung, adipose tissue, etc.). 
Nowadays, the biological role of ENPP1 is not fully 
understood, but there are two groups of evidences 
concerning the ENNP1 significance in pathogenesis of 
some pathological processes and diseases. 
The first group is about the ability of ENPP1 to 
influence insulin sensitivity by downregulating insulin 
receptor signaling (Dong et al., 2005). It was shown that 
over-expression of ENPP1 inhibits tyrosine kinase 
activity with subsequent diminishing insulin receptor 
autophosphorylation in various cells (Maddux and 
Goldfine, 2000). This property of ENPP1 is considered 
to be in association with insulin resistance and type 2 
diabetes (Goldfine et al., 2007). 
The second group of data is related to the processes 
of ectopic calcification. It is known that inorganic 
Pyrophosphate (PPi) is one of the most important 
inhibitor of soft tissues mineralization (Abedin et al., 
2004; Shao et al., 2006). The main way of PPi 
generating is hydrolysis of extracellular nucleoside 
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triphosphates, particular ATP, due to ENPP1 specific 
enzymatic activity (Johnson et al., 2005; Towler, 2005). 
When the activity of ENNP1 falls off the formation of 
PPi is disturbed and calcification of arteries may develop 
in many cases. The massive arterial calcification is the 
most impressive feature in genetically knocked out mice 
(ENPP1 -/-) and in humans who have defective ENNP1 
gene (Johnson et al., 2005). 
As a general rule, Acute Coronary Syndrome (ACS) 
is the consequence of atherosclerotic lesions appearing in 
arterial walls. It is well known that one of the main risk 
factors of atherosclerosis is type 2 diabetes which is 
frequently and tightly associated with insulin resistance. 
On the other hand, the coronary arteries calcification, as 
shown in many studies, is an adverse prognostic feature 
with regard to myocardial infarction in patients with 
atheromatous plaques (Lehto et al., 1996). 
Taking into consideration the stated above, a relation 
of various Single-Nucleotide Polymorphisms (SNPs) of 
ENPP1 gene to ACS is of great interest. The most widely 
investigated ENPP1 SNP in genotype-phenotype 
association studies is the polymorphism K121Q. In this 
SNP located in exon 4, a lysine (K) is substituted by a 
glutamine (Q) at codon 121 (Pizzuti et al., 1999). 
There are some studies in which association of the 
ENPP1 K121Q polymorphism with early onset of 
coronary artery disease in Caucasians has been 
investigated (Endler et al., 2002; Bacci et al. 2005), but 
the data obtained in various ethnic groups remain 
controversial (Chen et al., 2006). 
The aim of the present study was to perform a case-
control study on representatives of the Ukrainian 
population in order to assess the possible association of 
the ENPP1 K121Q polymorphism with ACS in subjects 
of both genders who had normal and overweight levels 
of Body Mass Index (BMI). 
Materials and Methods 
Subjects 
The study recruited 118 ACS patients (78% men and 
22% women) from 32 to 78 years of age (mean age [± SE] 
55.9±0.89) admitted to Sumy Clinical Hospital No.1. 
Diagnosis of ACS was established on the basis of 
clinical, electrocardiography and biochemical 
examinations according to the recommendations of 
WHO experts and also according to recommendations of 
European and American cardiologic societies (Antman et 
al., 2004; Thygesen et al., 2007). Patients with hereditary 
and congenital diseases, severe metabolic pathologies 
including a severe form of diabetes mellitus, marked renal 
and liver failures, deficiencies of the haemostatic system, 
oncology and systemic pathologies, chronic heart failure 
of IIB-III stage, true cardiogenic shock were excluded 
from the study group. 
The control group consisted of 110 clinically healthy 
individuals with the absence of cardio- and 
cerebrovascular pathologies, as confirmed by medical 
history, ECG and measurement of arterial pressure and 
biochemical data. The study had been previously 
approved by the Ethic Committee of the Medical Institute 
of Sumy State University. Appropriate informed consent 
was obtained from all patients and control subjects. The 
participants were unrelated Ukrainian people from the 
northeastern region of Ukraine.  
The subjects of both groups were divided into 
subgroups by gender and by BMI (BMI<25 kg/m
2
 and 
≥25 kg/m
2
). 
Blood sampling for genotyping was performed under 
sterile conditions into 2.7 ml tubes (SMonovette [Sarstedt, 
Germany]) containing EDTA potassium salt as an 
anticoagulant, samples were frozen and stored at -20°C. 
Genotyping of SNP 
DNA for genotyping was extracted from the 
venous blood using commercially available kits 
(Isogene Lab Ltd, Russia) according to the 
manufacturer’s protocol. To identify ENPPI K121Q 
polymorphism (rs1044498) the Polymerase Chain 
Reaction (PCR) with subsequent Restriction Fragment 
Length Polymorphism (RFLP) analysis was 
performed. Specific region of the ENPPI gene was 
amplified using a pair of specific primers: Upstream 
(sense)-5’ CTGTGTTCACTTTGGACATGTTG 3’ 
and downstream (antisense)-5’ 
GACGCTGGAAGATACCAGGCTG 3’. Primers were 
provided by Metabion (Germany). PCR was 
performed for 33cycles in a 25 µL volume containing 
50-100 ng of DNA, 5 µL 5X PCR-buffer, 1.5 mM 
magnesium sulfate, 200 µM of each dNTP, 15pM of 
each primer and 0.75U of Taq DNA polymerase 
(Thermo Scientific, USA). PCR was carried out in a 
termocycler GeneAmp PCR System 2700 (Applied 
Biosystems, USA). Six microlitres (6 µL) of the PCR 
products (238bp) were subjected to digestion with 5U 
Eco47I (AvaII) (Thermo Scientific, USA) and 
incubated at 37°С for 18 h. In case of the presence of 
cytosine at the position 48213 of the exon 4, Eco47I 
restriction enzyme produces two fragments of 148 and 
90bp in length. Substitution of cytosine for adenine 
prevents restriction and the amplified fragment of the 
exon 4 (238bp) can not be cleaved. The restriction 
fragments were separated by electrophoresis and 
analysed on an ethidium bromide-stained 2.5% agarose 
gel visualized using ultraviolet transillumination. 
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Statistical Analysis 
The normal distribution and homogeneity of 
variances were tested before further statistical analyses. 
The comparison of variables between the groups of 
genotypes was performed using two-tailed Student’s t-
test. The χ2-test was used for comparison of the allele 
and genotype frequencies between different studied 
groups and subgroups. Odds ratio was evaluated by 
using the logistic regression method. The differences 
were considered statistically significant with a P-value 
<0.05. All statistical analyses were performed using the 
Statistical Package for Social Science program (SPSS for 
Windows, version 17.0, SPSS Inc., Chicago, IL). 
Results 
The clinical characteristics of 118 patients with ACS 
and 140 healthy controls are summarized in Table 1. No 
differences between the groups were noted with respect 
to sex, age or body mass index. Atherogenic risk factors 
(including cigarette smoking, hypertension, total 
cholesterol and glucose concentration) were significantly 
more prevalent in the ACS patient group. 
In Figure 1 the results of RFLP analysis of ENPP1 
K121Q polymorphism are demonstrated. In both groups 
we studied, the genotype distributions of the ENPP1 
K121Q polymorphism were in Hardy-Weinberg 
equilibrium. The minor allele frequencies of SNP were 
not significantly different between the ACS (0.18) and 
control (0.12) groups. These frequencies were 
comparable with other studies using the same SNP in 
populations of European descent (Bottcher et al., 2006; 
Morandi et al., 2009). 
For genotype case-control analysis we took into 
consideration two subgroups (KK and KQ+QQ) since 
there were very few minor allele homozygotes QQ both 
in ACS (3 individuals) and in control (0 subjects) 
groups. As shown in Table 2, major allele homozygotes 
KK and carriers of minor allele KQ+QQ were detected 
in 66.9 and 33.1% of the ACS group, respectively 
(control group: 75.5 and 24.5%). The differences in the 
distribution of allelic variants between the ACS and 
control groups were not statisticaly significant. Such 
conclusion was true when subjects of both groups were 
divided into subgroups by gender but not by BMI. 
Using logistic regression analysis (Table 3), it was 
estimated that in persons with BMI <25 kg/m
2
,
 
carrying 
of minor allele (KQ+QQ) was significantly associated 
with ACS (OR=3.939; 95% CI, 1.148-13.524, P = 
0.029). The same could not be said about individuals 
with overweight (BMI≥25 kg/m
2
).  
Discussion 
In the present study, we explored associations 
between genetic variation in the ENPP1 gene and ACS 
risk. Analyzing the SNP of this gene we found that 
K121Q polymorphism in exon 4 was associated with 
ACS in the representatives of Ukrainian population only 
with normal (BMI<25 kg/m
2
), but not enhanced weight. 
The risk of ACS in not-overweight persons who were 
carriers of minor Q-allele was 3.9 fold greater as 
compared with main K-allele homozygotes.  
A functional missense DNA polymorphism in exon 4 
causes an amino acid change from lysine to glutamine at 
codon 121 (K121Q) (Pizzuti et al., 1999). Studies in 
vitro have shown that the Q variant of ENPP1 binds 
insulin receptors more strongly than the K variant and 
reduces insulin receptor autophosphorylation 
(Costanzo et al., 2001). It is therefore a stronger 
inhibitor of insulin signaling. 
In this connection wide range of case-control studies 
were conducted to asses the possible association between 
the ENPP1 gene K121Q polymorphism and (1) insulin 
resistance, (2) Type 2 Diabetes Mellitus (T2DM) and (3) 
overweight/obesity in many Caucasian and not-Caucasian 
populations (Goldfine et al., 2007). Although the published 
results are rather contradictory, it can be concluded that in 
many cases there are positive associations between Q 
variant of ENPP1 gene and aforementioned pathological 
conditions. 
All of these conditions are considered to be tightly 
pathogenetic connected with atherosclerotic process 
which is the main cause of ACS. This should be taken 
into account when studying relationship of the ENPP1 
gene SNPs to cardiovascular diseases. 
There is evidence suggesting that the Q allele is 
associated with an increased risk of earlier onset of 
myocardial infarction (Endler et al., 2002; Bacci et al., 
2005). This association may be secondary to the effect of 
the Q allele on insulin resistance, T2DM and 
overweight/obesity which all predispose to 
atherosclerosis (Fig. 2). 
In our study, we showed that ENPP1 gene K121Q 
polymorphism is related to ACS only in nondiabetic 
patients with normal weight and fasting glucose levels. It 
suggested the possible impact of this SNP on ACS not 
only by overweight/obesity and T2DM, but also by 
processes witch cause coronary insufficiency, i.e., 
atherosclerosis and arterial calcification. 
The influence of ENPP1 overexpression on arterial 
wall may be in two different ways (Fig. 3). On the one 
hand, downregulating insulin receptor signaling by 
ENPP1 leads to insulin resistance and contribute to 
atherosclerotic lesions development. On the other hand, 
enhanced enzymatic activity of ENPP1 should increase 
the formation of PPi which is one of the most potent 
anticalcinogenic factor that can prevent arterial wall 
calcification. 
It is yet not known how K121Q polymorphism 
impacts on enzymatic feature of ENPP1. This is a 
question that needs to be under further investigation. 
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Fig 1. Analysis of ENPP1 K121Q polymorphism. Results of restriction fragment electrophoresis of polymerase chain reaction 
amplification products. M-molecular marker (bp-base pairs), lanes 3, 4, 9, 10, 11 (KK genotype); lanes 1, 2, 7, 8 (KQ 
genotype); lanes 5, 6-(QQ genotype)  
 
 
 
Fig. 2. Possible ways of ENNP1 Q121 allele impact on the pathogenesis of acute coronary syndrome 
 
 
 
Fig. 3. Two possible opposite effects of ENPP1 overexpression on the wall of coronary arteries 
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Table 1. Clinical parameters of Acute Coronary Syndrome (ACS) and healthy (control) subjects  
 Subjects 
 ----------------------------------------------------------------------------------------------------------- 
Parameters ACS (n = 118) Control (n = 110) P-value 
Sex, male/female, n/n 92/26 78/32 0.221* 
Age, years 55.9±0.89 54.0±0.74 0.105 
Current smokers, n (%) 54 (45.8) 29 (26.4) 0.002* 
BMI, kg/m2 28.5±0.41 27.1±0.41 0.022 
SBP, mm Hg 140.8±1.7 124.6±1.0 <0.001 
DBP, mm Hg 89.5±0.9 80.2±0.7  <0.001 
TC, mmol/L 6.4±0.13 5.6±0.25  0.004 
HDL-C, mmol/L 1.0±0.12 1.4±0.10 0.012 
Fasting glucose, mmol/L 5.8±0.6 4.7±0.7 <0.001 
 
Table 2. Genotypes of ENPP1 K121Q polymorphism in patients with Acute Coronary Syndrome (ACS) and control subjects  
 Total  Men  Women   
 ------------------------------------------- ------------------------------------------ ------------------------------------------- 
 ACS group Control group ACS group Control group ACS group Control group 
Genotype (n = 118) (n = 110) (n = 92) (n = 78) (n = 26) (n = 32) 
KK 79 (66.9) 83 (75.5) 62 (67.4) 58 (74.4) 17 (65.4) 25 (78.1) 
KQ+QQ 39 (33.1) 27 (24.5) 30 (32.6) 20 (25.6) 9 (34.6) 7 (21.9) 
OR (95% CI) 1.518 (0.850-2.709) 1.891 (0.590-6.056) 1.403 (0.718-2.741) 
P-value 0.158  0.284  0.321 
 
Table 3. Genotypes of ENPP1 K121Q polymorphism in Acute Coronary Syndrome (ACS) and control subjects with normal (<25 
kg/m2) and enhanced (≥25 kg/m2) Body Mass Index (BMI)  
 BMI<25  BMI≥25 
 ----------------------------------------------------- ---------------------------------------------- 
 ACS Control ACS Control 
Genotype (n = 21) (n = 32) (n = 97) (n = 78) 
KK 11 (52.4) 26 (81.3) 68 (70.1) 57 (73.1) 
KK+KQ 10 (47.6) 6 (18.7) 29 (29.9) 21 (26.9) 
OR (95% CI) 3.939 (1.148-13.524)  1.158 (0.597-2.246) 
P-value 0.029  0.665 
 
Conclusion 
In the present study, genotypes with minor allele 
(KQ+QQ) for ENPP1 K121Q polymorphism were 
observed as a possible genetic risk factor for ACS only 
in persons with BMI <25 kg/m
2
. It is more likely that 
these genotypes affect ACS not through the traditional 
risk factors (overweight/obesity, insulin resistance and 
type 2 diabetes) but by direct or undirect influence on 
pathologic processes in the wall of the coronary vessels 
(atherosclerosis and arterial calcification). 
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